Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06132828 | Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 216 | Zhejiang Doer Biologics Co., Ltd.INDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06227377 | QTX3034 in Patients With KRAS G12D Mutation | recruiting | Phase 1 | 250 | Quanta TherapeuticsINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06723236 |
| A Study of MGC028 in Participants With Advanced Solid Tumors |
| recruiting |
| Phase 1 |
| 124 |
| MacroGenicsINDUSTRY |
| 1 |
| Apr 27, 2026 |
| clinicaltrials |
| NCT07439094 | A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 140 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06801002 | Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies | recruiting | Phase 1 | 25 | Jabez Bioscience, IncINDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06816992 | ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC | recruiting | Phase 1 | 76 | ORIC PharmaceuticalsINDUSTRY | 3 | Apr 24, 2026 | clinicaltrials |
| NCT01787500 | Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery | completed | Phase 1 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT02661542 | Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas | completed | Phase 1 / Phase 2 | 106 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05951608 | A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 216 | AkesoINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06308263 | Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303) | completed | Phase 1 | 12 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07541573 | GTB-5550 in Advanced Solid Tumors | recruiting | Phase 1 | 175 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05036291 | A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors | terminated | Phase 1 | 25 | Ningbo Newbay Technology Development Co., LtdINDUSTRY | 2 | Apr 22, 2026 | clinicaltrials |
| NCT06779851 | A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors(SUMMIT-1) | terminated | Phase 1 | 20 | Bright Peak Therapeutics IncINDUSTRY | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | recruiting | Phase 1 / Phase 2 | 295 | Verastem, Inc.INDUSTRY | 2 | Apr 22, 2026 | clinicaltrials |
| NCT06532565 | Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors | recruiting | Phase 1 | 154 | Gilead SciencesINDUSTRY | 2 | Apr 21, 2026 | clinicaltrials |
| NCT07346846 | A Study of BGM-2121 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 35 | BioGate Precision Medicine Corp.INDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07542704 | A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies | not yet recruiting | Phase 1 | 48 | Kumquat Biosciences Inc.INDUSTRY | 0 | Apr 21, 2026 | clinicaltrials |
| NCT01281176 | High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06326411 | A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors(NST-628) | recruiting | Phase 1 | 230 | Nested Therapeutics, IncINDUSTRY | 2 | Apr 20, 2026 | clinicaltrials |
| NCT06892379 | A Study of HS-20110 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 475 | Hansoh BioMedical R&D CompanyINDUSTRY | 2 | Apr 20, 2026 | clinicaltrials |
| NCT07539285 | A Study of HDM2024 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 63 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT03317743 | Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors | completed | Phase 1 | 32 | Idience Co., Ltd.INDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03881488 | Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies | completed | Phase 1 | 100 | Compass TherapeuticsINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04174716 | Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS)(VASTUS) | completed | Phase 1 / Phase 2 | 108 | Idience Co., Ltd.INDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04387071 | CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma | terminated | Phase 1 / Phase 2 | 2 | University of Southern CaliforniaOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05605119 | First in Human, Dose Escalation, Dose Expansion Study of AUR105(SURYA-1) | terminated | Phase 1 | 17 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05607199 | A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics(BHARAT-1) | terminated | Phase 1 | 27 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05865002 | A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1) | recruiting | Phase 1 | 50 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06544655 | A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors | active not recruiting | Phase 1 | 213 | Bristol-Myers SquibbINDUSTRY | 3 | Apr 17, 2026 | clinicaltrials |
| NCT06777316 | A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 110 | Cogent Biosciences, Inc.INDUSTRY | 2 | Apr 17, 2026 | clinicaltrials |
| NCT00479128 | Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors | active not recruiting | Phase 1 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06082960 | Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors | active not recruiting | Phase 1 | 45 | Gilead SciencesINDUSTRY | 3 | Apr 16, 2026 | clinicaltrials |
| NCT06959706 | Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 50 | Tagworks Pharmaceuticals BVINDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07380334 | A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 200 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05275478 | Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors | terminated | Phase 1 / Phase 2 | 110 | Tango Therapeutics, Inc.INDUSTRY | 2 | Apr 15, 2026 | clinicaltrials |
| NCT06799637 | Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments | recruiting | Phase 1 / Phase 2 | 350 | Evopoint Biosciences Inc.INDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05071846 | MVX-ONCO-2 in Advanced Solid Tumors | active not recruiting | Phase 1 | 6 | University Hospital, GenevaOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT06718621 | A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 14, 2026 | clinicaltrials |
| NCT04799054 | A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 188 | Ascendis Pharma Oncology Division A/SINDUSTRY | 6 | Apr 13, 2026 | clinicaltrials |
| NCT05120596 | First in Human Study of T3P-Y058-739 (T3P) | recruiting | Phase 1 / Phase 2 | 100 | T3 Pharmaceuticals AGINDUSTRY | 3 | Apr 13, 2026 | clinicaltrials |
| NCT05423262 | A Study of TRK-950 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 49 | Toray Industries, IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05879627 | To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors | terminated | Phase 1 | 93 | Bio-Thera SolutionsINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06143774 | Study of TRX-920 for Patients With Advanced Solid Tumors | recruiting | Phase 1 | 30 | TaiRx, Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06362369 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | recruiting | Phase 1 / Phase 2 | 126 | 7 Hills Pharma, LLCINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06487624 | An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors | recruiting | Phase 1 | 50 | FBD Biologics LimitedINDUSTRY | 3 | Apr 13, 2026 | clinicaltrials |
| NCT06810544 | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | recruiting | Phase 1 / Phase 2 | 191 | Tango Therapeutics, Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07326488 | A Study of MHB009C in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07509684 | A Phase Ib/II Study Evaluating Injectable ALK-N001 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 190 | Zhejiang Anglikang Pharmaceutical Co., Ltd.INDUSTRY | 0 | Apr 13, 2026 | clinicaltrials |
| NCT03594422 | A Study of HQP1351 in Patients With GIST or Other Solid Tumors | recruiting | Phase 1 | 100 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 27, 2026source: clinicaltrials